[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20022531D0 - Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases - Google Patents

Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases

Info

Publication number
NO20022531D0
NO20022531D0 NO20022531A NO20022531A NO20022531D0 NO 20022531 D0 NO20022531 D0 NO 20022531D0 NO 20022531 A NO20022531 A NO 20022531A NO 20022531 A NO20022531 A NO 20022531A NO 20022531 D0 NO20022531 D0 NO 20022531D0
Authority
NO
Norway
Prior art keywords
amyloid
alzheimer
vaccine
prevention
treatment
Prior art date
Application number
NO20022531A
Other languages
Norwegian (no)
Other versions
NO20022531L (en
Inventor
Robert Chalifour
Lise Hebert
Xianqi Kong
Francine Gervais
Original Assignee
Neurochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Inc filed Critical Neurochem Inc
Publication of NO20022531D0 publication Critical patent/NO20022531D0/en
Publication of NO20022531L publication Critical patent/NO20022531L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20022531A 1999-11-29 2002-05-28 Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases NO20022531L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16859499P 1999-11-29 1999-11-29
US72484200A 2000-11-28 2000-11-28
PCT/CA2000/001413 WO2001039796A2 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Publications (2)

Publication Number Publication Date
NO20022531D0 true NO20022531D0 (en) 2002-05-28
NO20022531L NO20022531L (en) 2002-07-12

Family

ID=26864284

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022531A NO20022531L (en) 1999-11-29 2002-05-28 Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases

Country Status (13)

Country Link
EP (1) EP1235587A2 (en)
JP (1) JP2004500354A (en)
KR (2) KR20080059676A (en)
CN (1) CN1433321A (en)
AU (1) AU784312B2 (en)
BR (1) BR0016022A (en)
CA (1) CA2388559A1 (en)
HK (1) HK1049279A1 (en)
IL (1) IL149924A0 (en)
MX (1) MXPA02005576A (en)
NO (1) NO20022531L (en)
NZ (1) NZ540564A (en)
WO (1) WO2001039796A2 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CA2400838C (en) * 2000-02-21 2013-04-23 Pharmexa A/S Novel method for down-regulation of amyloid
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
AU2007200047B2 (en) * 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AR038568A1 (en) * 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2491611A1 (en) * 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
MXPA05013977A (en) * 2003-06-23 2006-03-09 Neurochem Int Ltd Methods and compositions for treating amyloid-related diseases.
DK2336147T3 (en) * 2003-12-17 2014-06-10 Wyeth Llc BETA-IMMUNOGEN-PEPTIDE CARRIER CONJUGATES AND PROCEDURES FOR PRODUCING THEREOF
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
JP5145537B2 (en) 2004-12-22 2013-02-20 ビーエイチアイ リミテッド パートナーシップ Methods and compositions for treating amyloid-related diseases
KR100851035B1 (en) 2005-08-23 2008-08-11 대한민국 - - Pharmaceutical composition and composition for screening therapeutics to preventing and treating of -amyloid accumulation in brain comprising GCP-Glutamate carboxypeptidase- as an active ingredient method for screening using said composition
JP2009516654A (en) 2005-11-10 2009-04-23 ロスキャンプ リサーチ， エルエルシー Regulation of angiogenesis by A-beta peptide
KR101667623B1 (en) 2005-11-30 2016-10-19 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
ES2527661T3 (en) 2005-11-30 2015-01-28 Abbvie Inc. Scanning method, process for purifying non-spreadable Abeta oligomers, selective antibodies against said spreadable Abeta oligomers and a process for making said antibodies
NO346105B1 (en) 2005-12-12 2022-02-21 E Hoffmann La Roche Ag AMYLOID-BETA-4 ANTIBODIES WITH GLYCOSYLATED ASPARAGIN IN THE VARIABLE REGION
KR101236611B1 (en) * 2005-12-12 2013-03-04 에이씨 이뮨 에스.에이. Therapeutic vaccine
EP2004688B2 (en) 2006-03-23 2014-03-05 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
ME01758B (en) * 2006-07-14 2014-09-20 Genentech Inc Humanized antibody against amyloid beta
EP2468770B1 (en) 2006-07-14 2017-12-20 AC Immune S.A. Humanized antibody against amyloid beta.
BRPI0719763A2 (en) * 2006-10-02 2014-01-28 Ac Immune Sa ANTIBODY, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, CELL, COMPOSITION, MIXTURE, USE OF A CHEMICAL ANTIBODY OR A FRAGMENT OF THE SAME OR A FRAGMENT OF THE SAME AND / OR A PART OR A FUNCTION OR A PART OR A FUNCTION MIXTURE, METHODS FOR PREPARING A PHARMACEUTICAL COMPOSITION OR MIXTURE, TO PREVENT, TREAT OR RELIEVE THE EFFECTS OF A DISEASE, DIAGNOSTIC DISEASE, OR CONDITION ASSOCIATED WITH A DETERMINATION OF THE DETERMINATION OF CAROGUE DETERMINATION IN A FABRIC AND / OR BODY FLUIDS, TEST KITS FOR DISEASE AND DIAGNOSTIC TESTING AND CONDITIONS ASSOCIATED WITH AMYLOID, LIGHT CHAIN VARIABLE REGION, HEAVY CIRCLE, GENELE DESENGER, GENELE DIAGET LINES PRE-FORMED BETA-AMYLOID FIBERS TO PREVENT ABETA-INDUCED NEURON DEGRADATION, TO DIAGNOSE A PREDISPOSITION TO A DISEASE OR CO NDITION ASSOCIATED WITH AMYLOID IN A PATIENT, TO MONITOR MINIMUM RESIDUAL DISEASE IN A PATIENT, TO PROGNOSE LIABILITY OF A PATIENT WHO IS TREATED WITH AN ANTIBODY OR A COMPOSITION OF VACCINE, TO REDUCE THE CARBON LOAD TO THE CIRCLE THE NUMBER OF PLATES IN AN ANIMAL BRAIN, TO REDUCE THE TOTAL SOLUBLE OPEN QUANTITY IN AN ANIMAL BRAIN AND TO HOLD OR INCREASE COGNITIVE MEMORY CAPACITY IN A MAMMALIAN.
ES2533463T3 (en) 2006-10-12 2015-04-10 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8106015B2 (en) 2007-04-20 2012-01-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide
JP2010528583A (en) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム Humanized antibody against amyloid β
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
JP5889529B2 (en) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー Treatment of amyloidogenic diseases
EP2586795B1 (en) 2007-10-05 2018-05-16 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2273273A1 (en) * 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease
CN102933601B (en) 2010-04-15 2016-06-08 Abbvie公司 Amyloid beta binding proteins
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
CN103298833B (en) 2010-08-14 2015-12-16 Abbvie公司 Amyloid beta associated proteins
PL3166970T3 (en) 2014-07-10 2021-09-13 Bioarctic Ab Improved a-beta protofibril binding antibodies
MY180297A (en) 2015-06-24 2020-11-27 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
RU2753390C1 (en) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Bispecific antibodies to human cd20/human transferrin receptor and methods for their use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN108350052A (en) 2015-11-09 2018-07-31 英属哥伦比亚大学 Epitope in amyloid beta intermediate region and its conformation antibodies selective
EP3374383A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
CN109476729A (en) 2016-07-18 2019-03-15 英属哥伦比亚大学 The antibody of amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245003T3 (en) * 1996-08-27 2005-12-16 Praecis Pharmaceuticals Incorporated MODULATORS OF THE AGGREGATION OF BETA-AMYLOOID PEPTIDES THAT INCLUDE D-AMINO ACIDS.
NO314086B1 (en) * 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
AU4529800A (en) * 1999-05-05 2000-11-21 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof

Also Published As

Publication number Publication date
WO2001039796A2 (en) 2001-06-07
JP2004500354A (en) 2004-01-08
HK1049279A1 (en) 2003-05-09
AU1847301A (en) 2001-06-12
WO2001039796A3 (en) 2001-12-06
EP1235587A2 (en) 2002-09-04
MXPA02005576A (en) 2002-12-13
CA2388559A1 (en) 2001-06-07
NZ540564A (en) 2007-04-27
IL149924A0 (en) 2002-11-10
CN1433321A (en) 2003-07-30
KR20080059676A (en) 2008-06-30
NO20022531L (en) 2002-07-12
AU784312B2 (en) 2006-03-09
KR20020073341A (en) 2002-09-23
BR0016022A (en) 2002-08-06

Similar Documents

Publication Publication Date Title
NO20022531D0 (en) Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases
NO20014046D0 (en) Gabapentin derivatives for the prevention and treatment of visceral pain
NO20015773D0 (en) Prevention and treatment of amyloidogenic disease
LTPA2015001I1 (en) Thioflavin derivatives and their use for diagnosis and therapy of Alzheimer's disease
IS5500A (en) Medicinal preparations for the stimulation and treatment of gastrointestinal disorders and related diseases
NO994014D0 (en) Arylsulfonamides and analogs thereof and their use in the treatment of neurodegenerative diseases
SI1303272T1 (en) Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease
HUP0103654A2 (en) Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
NO20004098D0 (en) Methods and preparations for the treatment of macrophage-mediated disorders
NO972972L (en) Compositions for the treatment of dermatological disorders and methods for their use
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
NO20014314L (en) Compositions and methods for the treatment of staphylococcal infection
NO20014617D0 (en) 1-Arensulfonyl-2-aryl pyrrolidine and piperidine derivatives for the treatment of CNS diseases
DE69836209D1 (en) PREVENTION AND TREATMENT OF HEPATOCELLULAR CANCER
NO20001869L (en) Procedure for the treatment of Alzheimer's disease
NO20023448L (en) Drug combination for the treatment of depression and related disorders including mirtazapine
NO20000771D0 (en) Use of fanquinone for the treatment of Alzheimer's disease
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
NO20020784L (en) Medication for the treatment of fractures
PT1152762E (en) USE OF DEOXYGEGANIN IN THE TREATMENT OF ALZHEIMER'S DEMENTIA
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
PL377110A1 (en) Prevention and treatment of alzheimer's disease
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease
NO20013651D0 (en) Use of phosphorus inorganic compounds for the prophylactic and therapeutic treatment of infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application